Daye

Daye is a female-founded gynae health start-up focused on addressing the gender health gap. Their flagship product, the world’s first pain-relieving tampon, has already assisted over 75,000 women & AFAB individuals to manage menstrual cramps. In addition to this, they have also launched a second-generation tampon that enables at-home detection of vaginal infections, STIs, and HPV. Looking ahead, Daye aims to create solutions for under-served gynae health conditions such as endometriosis, PCOS, and menopause. Their vision for the next five years includes building an ecosystem where every woman can monitor and improve her health via her smartphone. Having secured a £10.00M Series A investment on 26 October 2022, Daye has gained the support of notable investors such as Hambro Perks, Simplyhealth, Cross-Border Impact Ventures, Michelle Tempest, MMV Europe & Asia-Pacific, and Fiona Pathiraja. The company, based in the United Kingdom, operates within the biotechnology, health care, health and wellness, and women's health industries.